Presenter's Information
Alan C. Yeung, MD
Country | USA |
Specialty | Interventional Cardiologist |
- Aortic Dissection During TAVR
- The UPSTREAM Management of Aortic Stenosis
- New Device Platform to Prevent Structural Heart Intervention Complications
- Hostile Anatomy - LVOT Calcification
- How Recent Guidelines will Change the Practical Indication of TAVR in the Coming Years?
- [Featured Lecture 1] The UPSTREAM Management of Aortic Stenosis
- Balloon Expandable Valves. New Understandings about Sizing, Positioning, and Repeating
- Overview of Cardiac Arrest During Structural Heart Intervention
- Optimal Valve Choice in Various TAVR: A Complex Equation to Select One
- Antithrombotic Strategy in PCI and AF Patients: Updated Strategy
- Many Many Stents: What Should I Select?
- Cerebral Protection During TAVR: Why and How?
- Expanding Indication of TAVR: Ongoing Trials and Expectations
- Sapien 3 THV with Future Coronary Access
- Case 1: Complex LM/Multivessel Disease - Hybrid Revascularization
- PCI, CABG, or Both: Current Status of Hybrid Coronary Revascularization
- Expert Case Review: PCI for Severely Calcified In-Stent Restenosis
- TAVR in Low Risk Patients
- Sapien 3 or Evolut R: Different Indications?
- MV and TV Intervention: Preparing for the Next Revolution
- TAVR: Advancing Your Skills: Beyond the Basics
- How to Manage Complication TAVR Case
- Updates on Antiplatelet Therapy in Cardiovascular Disease
- Contemporary DES Thrombosis and Restenosis: Incidence, Mechanisms, and Treatment
- Evolving TAVR Indications (Heart Failure, Asymptomatic AS, and AR)
- Contemporary and Future Metallic DES: What Do We Expect More from Ongoing PCI Trials?
- MV and TV Repair - Current Status and Innovative Future
- TVT Registry
- TAVR Clinical Trials
- PVL: How to Prevent and How to Treat?
- Sizing Strategy and PVL Management: Most Experienced Strategy
- TAVR for Low Risk Patients: Interventionist\'s Viewpoint
- The Evolution of Mitral and Tricuspid Valve Interventions: What It Is? and Where It Needs to Go?
- Experience, Current Status and Future of BRS in U.S. Real-World
- Technical Lessons for TAVR; Expert Experience
- Award Tribute
- Comparative Outcomes of Contemporary DES; Are There Major Difference?
- Low Coronary Ostium with Narrow or Wide Sinus
- Early Discharge Check List to Be Minimalist
- Frailty Assessment and How to Define Futile TAVR
- Next Issue: How to Manage Failed Transcatheter Heart Valve
- Complete Revascularization- The Future Mode of Revascularization in STEMI?
- Balloon Expandable System
- New Transcatheter Heart Valves
- Edward Sapien: Transfemoral
- TAVI: Future Perspectives
- Edward Sapien
- Coronary Obstruction: Treatment and Prevention
- Myocardial Bridge: Incidental Finding or Clinical Pathology?
- Invited Case Presentation & Focus Review: Multi-vessel Intervention
- Mediate a Dispute: Summary
- Promus-Element Stent
- In-Stent Restenosis - Stop ISR: How to Treat DES-ISR?: Summary
- The Updated Evidence-based Guidelines for the Use of Antiplatelet Therapies in ACS
- Clinical Decision Making in Patients with Left Main Disease
- Use of OCT in Treating a LAD/Diagonal Bifurcation Lesion
- Is It Real? Cytochrome P450 Genetic Polymorphisms, Varying Response to Clopidogrel, and Link to Clinical Outcomes : Global Perspective
- How to Teach and Train Innovation: US Approach
- Experiences of 2nd Generation OCT in Assessment of Complex Coronary Lesions; Can It Give Us Additive Useful Information?
- Association between CYP2C19 Genotype and Adverse Clinical Outcomes among PCI Patients: A Meta-analysis
- Optimizing the Role of New Anti-thrombotic Regimens in ACS - When, What and Why?
- Endothelial Dysfunction Associated with DES: How Important?
- New Technologies for Bifurcation: Main Vessel Centric vs Side-Branch Centric
- New Devices in Bifurcation Lesions: Do We Really Need One?
- Bifurcation Stenting: Implications of the Norfic Study
- What Makes Endeavor Different
- D2B: An Alliance for Quality
- TAXUS Real-World Experience from ARRIVE Registry
- Is There a Safety Advantage in the PC Based DES Systems? Possible Mechanisms
- Systemic Therapy: Pharmacologic Approach or Cell/Gene Therapy
- Technical Aspects and an Update on the EU and US ZOMAXX Clinical Trials
- What Are the Proper End Points for DES Trials?
- IVUS in Complex PCI
- Regional Photodynamic Therapy for Vulnerable Plaque Stabilization I: Antrin
- ABT 578 Drug-Eluting Stents II: Preclinical Observations and the Clinical Trial Strategy for the Abbott ZoMax Stent
- What Are The Proper End Points for DES Trial
- Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition with Tirofiban before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty(TIGER-PA) Pilot Trial
- Percutaneous Bypass: Rebirth as Treatment for CTO
- Bifurcation Stenoses: Is There a Solution in Sight ?
- Brachytherapy vs DES: Is the Answer in yet ?